Entera Bio

Entera Bio FCF Yield

The Free Cash Flow Yield of Entera Bio (ENTX) as of Oct 8, 2026 is -13.70 %. In the previous year, Free Cash Flow Yield was -12.50 % — a change of 9.62% (lower).

FCF Yield

-13.70 %

YoY

9.62%

Last updated:

Free Cash Flow Yield of Entera Bio is 2025 -13.70 % . Free Cash Flow Yield of Entera Bio was 2024 -12.50 % . It decreases by 9.62% lower compared to the previous year.

The Entera Bio FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-18.08 USD
Jan 1, 2019
-16.42 USD
Jan 1, 2020
-19.44 USD
Jan 1, 2021
-16.64 USD
Jan 1, 2022
-22.99 USD
Jan 1, 2023
-13.43 USD
Jan 1, 2024
-12.50 USD
Jan 1, 2025
-13.70 USD
The Entera Bio FCF Yield history
YEARFCF YieldYoY
-13.70 %+9.62%
-12.50 %-6.91%
-13.43 %-41.60%
-22.99 %+38.17%
-16.64 %-14.42%
-19.44 %+18.43%
-16.42 %-9.17%
-18.08 %+115.51%
-8.39 %+43.80%
-5.83 %-10.31%
-6.50 %—
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Free Cash Flow Yield of Entera Bio is -13.70 % in 2025.

Free Cash Flow Yield of Entera Bio changed from -12.50 % to -13.70 %, representing a 9.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Entera Bio since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Entera Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Entera Bio

All Key Metrics — Entera Bio